EN DE
Watch Prostatype Genomics AB for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Prostatype Genomics AB (PROGEN) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Prostatype Genomics AB stock SEK 0.09, price SEK 0.10, that is 11.7% below the price, quality 25 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SE · ISIN SE0014684569

PG Prostatype Genomics AB logo Thin data Nov 10, 2026

Prostatype Genomics AB

PROGEN · ST
Expensive, weak quality

Our calculation puts a fair price 12% below what the stock costs today.

Low debt
Revenue last quarter +86% vs. a year ago.
Mixed vs. peers (3/7)
Fair value kr 0.0874 · Overvalued
Quality 25/100
Weak Growth (revenue 5y −2.8 %/yr in SEK)
Negative free cash flow
Narrow moat 11/100 · thin data
Thin data
Estimate
Watch Prostatype Genomics AB for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 1,757 kr 0.0860 Fair Value kr 0.0874 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range kr 0.0860 – kr 1,757 · fair‑value band kr 0.0655 – kr 0.1092 · the kr 0.0990 price screens above the kr 0.0874 fair value. As of Nov 10, 2026.

Follow Prostatype Genomics in your weekly email

Every Wednesday you see whether Prostatype Genomics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, and tumor stage, as well as calculates the P-score.

Show moreShow less

Its test is based on database containing prostate cancer patients; and provides decision support for patients and doctors when making a treatment decision. The company was incorporated in 2007 and is headquartered in Solna, Sweden.

Stock analysis

Prostatype Genomics AB (PROGEN) currently trades at kr 0.0990, while our estimate is kr 0.0874, 12% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: kr 0.0655 (bear) to kr 0.1092 (bull), the price of kr 0.0990 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Prostatype Genomics AB reported revenue of 594K SEK in FY2025 versus 10.0K SEK in FY2021, a compound +177.6%/yr. Reported net income was −44.5M SEK in FY2025.

Key figures

Market cap 15.4M SEK (≈ $1.6M) Micro · P/S ratio 19.1 · EPS (TTM) kr −0.2600 · Return on equity −176% · Return on assets (EBIT) −77.1% (5-year average) · Operating margin −4,067% · Revenue (TTM) 805K SEK · Revenue growth (YoY) +85.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 11 out of 100 (low confidence).

What moves the price

The share trades about 95% below its 52-week high and 15% above its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at −12%, PROGEN screens richer than that median.

Fair Value

Bear kr 0.0655 Fair Value kr 0.0874 Bull kr 0.1092
Price kr 0.0990 · Downside -11.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 25/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 71
Are margins and returns getting better?
Cashflow 1
Do the profits arrive as real cash?
Financial strength 57
Debt, balance sheet and risk of trouble
Investment 36
Does it invest with discipline instead of growing at any price?
Low Volatility 13
How calm the share price moves, does not count
Price momentum 18
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.8%
Start year 2020 (pandemic). Over 10 years: +19.3% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−2,430.0% (2020) → −6,579.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

PROGEN screens overvalued: fair value 12% below the price. Compare with Thermo Fisher Scientific Inc →

Compare Prostatype Genomics AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 149 stocks

Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 25 · Bottom 25%
Fair Value upside −11.7% · Above median
Profitability
Return on assets −87.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 85.8% · Top 25%

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 0.58× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 19.13× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)18 · sector 12
FUTURE (revenue growth)100 · sector 40
PAST (return on equity)0 · sector 7
HEALTH (low debt)100 · sector 95
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
WuXi AppTec Co 603259 ¥150.30 ¥165.32 +10% vs PROGEN
Illumina, Inc ILMN $214.91 $234.44 +9% vs PROGEN
IQVIA Holdings IQV $275.15 $299.58 +9% vs PROGEN
Thermo Fisher Scientific Inc TMO $718.20 $686.04 −4% vs PROGEN
Danaher Corporation DHR $236.11 $209.18 −11% vs PROGEN
IDEXX Laboratories, Inc IDXX $696.64 $496.48 −29% vs PROGEN
Mettler-Toledo International Inc MTD $1,751 $655.06 −63% vs PROGEN
Agilent Technologies, Inc A $177.88 $64.53 −64% vs PROGEN
Lonza Group LONN CHF 661.00 CHF 153.50 −77% vs PROGEN
Waters Corporation WAT $475.52 $91.26 −81% vs PROGEN

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Prostatype Genomics AB: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Prostatype Genomics AB Fair Value". https://www.fairvalue-calculator.com/stock/PROGEN

Frequently asked questions

Is Prostatype Genomics AB (PROGEN) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is kr 0.0874 versus a price of kr 0.0990, about 12% lower (overvalued).
What is the fair value of PROGEN?
Our estimate for Prostatype Genomics AB is kr 0.0874 (as of Nov 10, 2026), built from audited fundamentals. The current price: kr 0.0990.
What is the quality score of PROGEN?
Prostatype Genomics AB has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Prostatype Genomics AB (PROGEN)?
Our calculated price target is the estimate of kr 0.0874 (as of Nov 10, 2026). Cautious scenario kr 0.0655, optimistic scenario kr 0.1092. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Prostatype Genomics AB stock forecast for 2026?
Our estimate puts fair value at kr 0.0874, about 12% lower versus a price of kr 0.0990 (overvalued). Cautious scenario kr 0.0655, optimistic scenario kr 0.1092. The calculation is refreshed regularly with new filings.
What is the revenue of Prostatype Genomics AB (PROGEN)?
Prostatype Genomics AB reported trailing-twelve-month revenue of about 805K SEK (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Prostatype Genomics AB (PROGEN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Prostatype Genomics AB it is kr 0.0874 per share (as of Nov 10, 2026), against a price of kr 0.0990.
Is Prostatype Genomics AB stock overvalued or undervalued in 2026?
As of Nov 10, 2026, PROGEN trades above its calculated fair value: price kr 0.0990, fair value kr 0.0874, a gap of about −12% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PROGEN?
No. The price is what the market pays today (kr 0.0990); the fair value is what the company's own numbers justify (kr 0.0874). For Prostatype Genomics AB the two are kr 0.0116 per share apart. That gap is exactly why we show both numbers side by side.
How much is Prostatype Genomics AB worth?
The market values Prostatype Genomics AB at about 15.4M SEK (market capitalisation, as of Nov 10, 2026). Per share that is kr 0.0990; our models calculate a fair value of kr 0.0874 per share.
What do the bullish and bearish scenarios say about PROGEN?
Our models span a range for Prostatype Genomics AB: cautious scenario kr 0.0655, base kr 0.0874, optimistic kr 0.1092 per share (as of Nov 10, 2026, price kr 0.0990). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Prostatype Genomics AB (PROGEN)?
Balance-sheet figures for Prostatype Genomics AB (as of Nov 10, 2026): return on equity −176.2%. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
How far is PROGEN from its 52-week high?
Prostatype Genomics AB trades at kr 0.0990, about 95% below its 52-week high of kr 1.95 and 15% above the low of kr 0.0860 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.0874 is for.
Which stocks are comparable to Prostatype Genomics AB?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, IDEXX Laboratories, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Prostatype Genomics AB stock attractive at the current price?
The data as of Nov 10, 2026: price kr 0.0990, calculated fair value kr 0.0874 (−12%), Quality Score 25/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Prostatype Genomics AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Prostatype Genomics AB (PROGEN)?
The closing price on Nov 10, 2026 was kr 0.0990. Our estimate is kr 0.0874, about 12% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Prostatype Genomics AB right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Prostatype Genomics AB

How large is the market capitalisation of Prostatype Genomics AB (PROGEN)?
The market capitalisation of Prostatype Genomics AB is 15.4M SEK (≈ $1.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Prostatype Genomics AB (PROGEN)?
The price-to-sales ratio of Prostatype Genomics AB is 19.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Prostatype Genomics AB (PROGEN)?
Earnings per share at Prostatype Genomics AB are kr −0.2600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Prostatype Genomics AB (PROGEN)?
The return on equity (ROE) of Prostatype Genomics AB is −176% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Prostatype Genomics AB (PROGEN)?
On an EBIT basis the return on assets of Prostatype Genomics AB is −77.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Prostatype Genomics AB (PROGEN)?
The operating margin of Prostatype Genomics AB is −4,067% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Prostatype Genomics AB (PROGEN)?
Revenue at Prostatype Genomics AB is growing +85.8% versus a year earlier (3y avg −4.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Prostatype Genomics AB (PROGEN) generate?
The free cash flow of Prostatype Genomics AB is −24.1M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Prostatype Genomics AB (PROGEN) hold?
Prostatype Genomics AB holds more cash than debt, 3.8M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Prostatype Genomics AB in the live analysis

One click puts Prostatype Genomics AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.